Yera-Alos, Isis B <br/><br/>
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.  [electronic resource] 

 -  BMC pharmacology & toxicology  Sep 2013 
 - 44 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2050-6511 
<br/><br/><label>Standard No.: </label>10.1186/2050-6511-14-44  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amputation, Surgical--statistics & numerical data<br/>Diabetic Foot--drug therapy<br/>Dose-Response Relationship, Drug<br/>Epidermal Growth Factor--administration & dosage<br/>Female<br/>Granulation Tissue--drug effects<br/>Humans<br/>Injections, Intralesional<br/>Male<br/>Middle Aged<br/>Product Surveillance, Postmarketing<br/>Prospective Studies<br/>Treatment Outcome<br/>Wound Healing--drug effects<br/>Young Adult